Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
General Radiation Oncology
Is there an increased risk of spinal cord myelopathy in patients who have heterozygous ATM mutations?
Can bone mets in the vertebral body be treated with radiation in patients with ATM mutations?
Related Questions
When do you prefer to use bolus for treating superficial tumors adjacent to or involving the skin surface, especially for complex surface anatomy in the pelvis, head/neck, and extremity regions?
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?
How do you manage a patient's pain from the skin tattoos placed at the CT simulation?
Would you ever re-irradiate the groin/inguinal region?
When do you offer adjuvant radiation therapy for a glomus tumor of uncertain malignant potential of the extremity resected with negative margins?
What dose and fractionation would you use for a non-operable solitary fibrous tumor in the lumbar vertebra with definitive intent?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
If an anatomical defect forms due to rapid disease response from pelvic radiation for large gynecological tumors, is it safe to proceed with a further radiotherapy boost
Do you constrain heterogeneity or hotspots when delivering spine SBRT for bone metastases?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?